Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Schedule of Segment Information (Details)

Segment Information - Schedule of Segment Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2020	Jul. 31, 2019	Jul. 31, 2020	Jul. 31, 2019	Oct. 31, 2019
Net Loss	$ (2,576,787)	$ (2,166,048)	$ (7,851,352)	$ (9,707,591)
Total operating costs and expenses	2,435,969	2,184,412	7,735,975	10,011,374
Less non-cash share-based compensation	(1,041,799)	(830,898)	(3,173,219)	(4,902,512)
Operating costs and expenses excluding non-cash share-based compensation	1,542,254	1,353,514	4,710,840	5,108,862
Total assets	9,361,781		9,361,781		$ 6,293,693
CAR-T Therapeutics [Member]
Net Loss	(402,223)	(723,128)	(1,527,586)	(4,240,347)
Operating costs and expenses excluding non-cash share-based compensation	182,007	442,621	752,170	1,688,301
Total assets	4,110,341		4,110,341		2,382,460
Cancer Vaccines [Member]
Net Loss	(172,881)	(573,005)	(538,748)	(573,005)
Operating costs and expenses excluding non-cash share-based compensation	70,061	407,010	235,391	407,010
Total assets	1,575,525		1,575,525		489,881
Anti-Viral Therapeutics [Member]
Net Loss	(268,704)		(578,208)
Operating costs and expenses excluding non-cash share-based compensation	149,075		370,093
Total assets	3,349,814		3,349,814
Cancer Diagnostics [Member]
Net Loss	(1,727,256)	(876,667)	(5,196,929)	(3,929,021)
Operating costs and expenses excluding non-cash share-based compensation	1,136,629	487,169	3,345,441	1,905,137
Total assets	78,723		78,723		3,119,246
Patent Licensing [Member]
Net Loss	(5,723)	6,752	(9,881)	(965,218)
Operating costs and expenses excluding non-cash share-based compensation	4,482	$ 16,714	7,745	$ 1,108,414
Total assets	$ 247,378		$ 247,378		$ 302,106